China

2020 Edition

Articles
Key Highlights of China’s New Drug Administration Law

On 26 August 2019, the Chinese legislature, the National People’s Congress (NPC), passed the new Drug Administration Law (DAL), which came into effect on 1 December 2019 and represents one of the most important milestones for the Chinese healthcare industry. This is only the second systematic and structural major revision…

China’s Role in Defeating Antimicrobial Resistance

According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the biggest threats to global health, food security, and development today. If this trend is not slowed or reversed, it could jeopardize many, if not most, of our medical advancements to date. Antimicrobials are essential for the…

Read the Full Version
Chinese Biotechs Flock to IPO in Hong Kong

2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland China, listing last year. The average…

Chinese Oncology Biotechs to Watch

Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we highlight four of China’s most inno…

HiNounou – Gamifying Preventative in China

As patients and consumers grow more educated and proactive in managing their own health and wellbeing, new ventures are hoping to serve their needs in not just prophylactic but also preventative health. HiNounou is a nifty little start-up based…

CEO Profile
Company Spotlight
Shirley Xu
President Greater China, Baxter

The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market has been left playing catch-up. As the Chinese government looks to…

Company Spotlight
Allergan China
Straddling Pharma, Medtech, Cosmetics & Digital

Within the industry, Allergan already stands out for the interesting composition of its portfolio. For China President White Wang, this was precisely the attraction. He enthuses, “Allergan is truly a very unique company. It is at once a pharma company, a medical…

Thanks for reading!

The Digital Version of the Healthcare & Life Sciences Review: China is available and optimized for desktop browsers.

Visit our website with your computer or download the pdf report

Read the Full Version

2020. Healthcare & Life Sciences Review was produced by Pharmaboardroom.

Copyright: All rights reserved. No part of this publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors. All the images belongs to its respective authors.

Senior Editor: Karen Xi
Report Coordinators: Lucía M. de Vidales, Manon Canicio, Asceline Dury
Report Assistant: Sara Curcio Lamas
Editor: Patrick Burton
Report Publisher: Diana Viola
Graphic Designer: Miriam León

PharmaBoardroom

Contact us

+44 20 7867 3717 info@pharmaboardroom.com

For media inquiries, please contact: media@pharmaboardroom.com

Address

PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT

Subscribe